抄録
The clinical effectiveness and safety of T-1982 were compared with those of cefmetazole (CMZ) in respiratory tract infections in the randomized double blind method. 289 patients were administered with one gram of T-1982 or two grams of CMZ by intravenous drip infusion twice a day for 14 days. The results were as follows; 1) Clinical efficacy rates were 87. 1% for T-1982 group and 83. 3% for CMZ group in overall cases; with 86.1% for T-1982 and 84.8% for CMZ in bacterial pneumonia, 77.8% for T-1982 and 83.3% for CMZ in mycoplasmal pneumonia or primary atypical pneumonia, and 88.1% for T-1982 and 82. \% for CMZ in the cases without pneumonia, respectively. Thus no significant difference was observed between the T-1982 group and the CMZ group. 2) The bacteriological responses of the patients to T-1982 and CMZ were favorable in 98. 2% and 98. 1%, respectively. No significant difference was observed. 3) No significant difference was noted between the two drug groups in incidence of adverse reaction. 4) As for the usefulness of the both treatment, committee judged to be useful with T-1982 in 82.1% of the cases and CMZ in 78.6%. Statistical tests showed no significant difference. From the results of this trial, it was concluded that T-1982 was as effective and as useful as CMZ in the treatment of respiratory tract infections as a 1/2 daily dose that of CMZ.
本文言語 | English |
---|---|
ページ(範囲) | 528-565 |
ページ数 | 38 |
ジャーナル | Chemotherapy |
巻 | 31 |
号 | 5 |
DOI | |
出版ステータス | Published - 1983 1月 |
外部発表 | はい |
ASJC Scopus subject areas
- 薬理学(医学)
- 感染症
- 薬理学
- 創薬
- 腫瘍学